Certain thiazole-carboxamides and acylamino-thiazoles

ABSTRACT

1-Amino-3-(4- or 5-substituted thiazol-2-oxy)-2-propanol and/or substituted amino derivatives thereof; 3-(4- or 5-substituted thiazol-2-oxy)-1,2-epoxypropane and 5-(4- or 5-substituted thiazol-2-oxymethylene)-oxazolidine and/or N- and/or 2-substituted oxazolidine derivatives thereof, and methods of making such compounds. The compounds are characterized by an aminocarbonyl or carbonylamino type substituent at the 5- or 4-position on the thiazole ring. The above 1-amino-3-(4- or 5-substituted thiazol2-oxy)-2-propanol and derivatives exhibit cardiovascular activity and are useful in the treatment of abnormal heart conditions in mammals. The 3-(4- or 5-substituted thiazol-2-oxy)-1,2epoxypropanes are useful as intermediates for the aforementioned cardiovascular agents. The 5-(4- or 5-substituted thiazol-2oxymethylene)-oxazolidine and derivatives are intermediates for the aforementioned cardiovascular agents and further exhibit cardiovascular activity and thus are useful in the treatment of abnormal heart conditions in mammals. The 1-amino-3-(4- or 5substituted thiazol-2-oxy)-2-propanol and derivatives can be prepared by base or acid hydrolysis of the corresponding 5-(4- or 5-aminocarbonylthiazol-2-oxymethylene)-oxazolidine or derivative; or by treatment of the corresponding 3-(4- or 5-substituted thiazol-2-oxy)-2,3-epoxypropane or derivative with the desired amine or amine derivative.

United States Patent Edwards [75] Inventor: John A. Edwards, Los Altos, Calif.

[73] Assignee: Syntex (U.S.A.) Inc., Palo Alto,

Calif.

[22] Filed: Mar. 14, 1974 [21] Appl. No.: 451,179

Related US. Application Data [63] Continuation-impart of Ser. No. 289,730, Sept. 15, l972, Pat. No. 3,850,945, which is a continuation-in-part of Ser. Nos. 193,172, Oct. 27, 1971, abandoned, and Ser. No. 343,945, March 22, 1973, abandoned, which is a continuation-in-part of Ser. No. 289,730, Sept. 15, 1972, which is a continuation-in-part of Ser. No. 193,172, Oct. 27, 1971, abandoned.

[52] US. Cl. 260/302 R; 260/243 B; 260/247.l; 260/268 H; 260/293.68; 260/2948 D; 260/3067 R; 260/3068 R; 424/200; 424/232; 424/246; 424/248; 424/250; 424/264; 424/267; 424/270 [51] int. Cl. C07d 91/32; C07d 91/34 [58] Field of Search 260/302 R, 306.8 R, 247.1, 260/268 H, 293.68, 268 C 156] References Cited UNITED STATES PATENTS 3,328,417 6/1967 McLoughlin et a] 260/302 R 3,715,369 2/1973 Possglt et a1. 260/302 R .3,803,l60 4/1974 Bosshard et al.... 260/302 R 3,803,161 4/1974 Wgi 260/3068 R July 29, 1975 Primary Examiner-Richard J Gallagher Attorney, Agent, or Firm-Lawrence S. Squires; William B. Walker 5 7 ABSTRACT l-Amino-3-(4- or S-substituted thiazol-2-oxy)-2- propanol and/or substituted amino derivatives thereof; 3-( 4- or 5-substituted thiazol-2-oxy l ,2- epoxypropane and 5-(4- or 5-substituted thia-zol-2- oxymethylene)-oxazolidine and/or N- and/or 2- substituted oxazolidine derivatives thereof, and methods of making such compounds. The compounds are characterized by an aminocarbonyl or carbonylamino type substituent at the 5- or 4-position on the thiazole ring. The above 1-amino-3-(4- or 5-substituted thiazol-2-oxy)-2-propanol and derivatives exhibit cardiovascular activity and are useful in the treatment of abnormal heart conditions in mammals. The 3-(4- or 5-substituted thiazol-2-oxy)-l,2-epoxypropanes are useful as intermediates for the aforementioned cardiovascular agents. The 5-(4- or 5-substituted thiazol-2- oxymethylene)-oxazolidine and derivatives are intermediates for the aforementioned cardiovascular agents and further exhibit cardiovascular activity and thus are useful in the treatment of abnormal heart conditions in mammals. The l-amino-3-(4- or S substituted thiazol-2-oxy)-2-propanol and derivatives can be prepared by base or acid hydrolysis of the corresponding 5-(4 or S-aminocarbonylthiazol-2- oxymethylene)-oxazolidine or derivative; or by treatment of the corresponding 3-(4- or 5-substituted thiazol-2-oxy)-2,3-epoxypropane or derivative with the desired amine or amine derivative.

50 Claims, N0 Drawings CERTAIN THIAZOLE-CARBOXAMIDES AND ACYLAMINO-TI-IIAZOLES CROSS REFERENCE TO RELATED APPLICATIONS This application is a continuation-in-part of US. Ser. No. 289,730, filed Sept. 15, 1972, now U.S. Pat. No. 3,850,945 which in turn is a continuation-in-part of US. Ser. No. 193,172, filed Oct. 27, 1971 and now abandoned; and of U8. Ser. No. 343,945, filed Mar. 22, 1973, and now abandoned which is also a continuation-in-part of US. Ser. No. 289,730, filed Sept. 15, 1972, which in turn is a continuation-in-part of application Ser. No. 193,172, filed Oct. 27, 1971 and now abandoned.

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates to 3-(4- or S-substituted thiazol-2-oXy)-propane derivatives and 4'- or S'- substituted thiazol-2-oxymethylene-oxazolidine derivatives and to methods of preparing such compounds. In a further aspect this invention relates to lamino-3-(4- or S-substituted thiazol-2-oxy)-2-propanol and 1- lsubstituted amino)- and/or 4- or 5'-substituted thia' zole derivatives thereof and to methods of preparing such compounds. In a still further aspect this invention relates to 3-(4- or 5-substituted thiazol-2-oxy)-l ,2- epoxypropane derivatives and to methods of preparing and using such compounds. In another aspect this invention relates to 4'- or 5'-substituted thiazol-2'- oxymethylene-oxazolidine derivatives and/or substituted oxazolidine derivatives thereof and to methods of preparing and using such compounds. This invention also relates to pharmaceutical compositions comprising the l-amino-3-(4- or 5-substituted thiazol-2-oxy)-2- propanol and derivatives, of the invention, and/or the 4'- or 5"substituted thiazol-2-oxy-methylene oxazolidine and derivatives, of the invention, and to methods of applying such compositions for the treatment of mammals.

2. The Prior Art At the present time, the compound frequently used in the United States for the treatment of several cardiac arrhythmias is propranolol (i.e. l-(isopropylamino)-3- l1-naphthyloxy)-2-propanol). This compound primarily achieves its therapeutic action by blocking cardiac B-adrenergic receptor sites and is a general B-adrenergic blocker which blocks the peripheral B-adrenergic receptor sites, such as those in the lung, as well as the B-adrenergic receptor sites in the heart. Propranolol is contraindicated in patients who suffer from asthma or chronic obstructive lung disease, because following its administration to such patients, an increase in airway resistance and bronchial constriction has been observed. Accordingly, I have now discovered potent cardiac selective B-adrenergic blocking agents which are effective for the treatment or palliation of cardiac arrhythmias, and which further can safely be used by patients suffering from asthma or chronic obstructive lung disease. The compounds are further effective for.

the treatment or palliation of angina pectoris and again can be safely applied to patients who also suffer from asthma or chronic lung disease.

SUMMARY OF THE INVENTION In summary the compounds of the invention can be represented by the following generic formula:

wherein Z is at either the 4- or'S-position of the thiazole ring and has the formula:

wherein R and R are independently selected from the group of hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, terminally substituted alkyl, and groups having the formulas (CH R R or (CH ),,R wherein n is a whole integer of from one through four, R and R are independently hydrogen and alkyl groups having one through four carbon atoms, and R is cycloalkyl having from three through eight carbon atoms; and wherein when Z is the group RII 40 then R cannot be hydrogen;

Y is selected from the group having the formulas:

comprises treating the corresponding 3-(4- or -Z- thiazoI-2-oxy)-l-alkylsulfonyl or phenylsulfonyl-2- propanol derivative at the 2,3-position with a strong base.

In summary the process of the invention for preparing the compounds, of the invention, wherein Y is the group CHOH-CI-I -Y' comprises treating the compounds of the invention wherein Y is CH-CH with ammonia or amine having the desired R and R substituent. Alternatively these compounds can be prepared, according to the invention, by hydrolysis of the corresponding Y is oxazolidine compounds of the invention.

In summary the process of the invention of preparing the compounds of the invention wherein Y is an oxazolidine group, in the Z is series, comprises condensation of a 2bromo or 2- chloro-thiazole having the desired 4- or 5-position substituent with a 5-hydroxymethyl-oxazolidine having the desired R R and R -substituents. All of the oxazolidine compounds can be prepared by treating the corresponding compounds of the invention where Y is an aminopropanol derivative with the desired R, R aldehyde or ketone.

In summary the pharmaceutical compositions of the invention include both solutions and solids or powders comprising one or more of the compounds, of the invention, wherein Y is an amino propanol type derivative and/or one or more compounds of the invention, wherein Y is an oxazolidine derivative in combination with a suitable pharmaceutical solution (e.g. sterile water) or pharmaceutical solid excipients.

The invention will be further described herein below.

DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS The compounds of the invention can be represented by the following sub-generic formulas:

4 3 z 2 O-CH -CH-CH,

5 o N-R c (III) R R" wherein R and R are independently selected from the group of hydrogen, lower alkyl, cycloalkyl having from three through seven ring atoms, lower alkenyl, phenyl, lower phenylalkyl, substituted phenyl, substituted lower phenylalkyl, hydroxy lower alkyl, (lower alkoxy) lower alkyl, lower alkyl (N-heterocyclic having from five through seven ring atoms including one or two heteroatoms selected from the group of nitrogen, oxygen and sulfur and wherein at least one of said heteroatoms is nitrogen) and groups having the formulas wherein n is a whole integer of from one through four; and R and R are independently hydrogen or lower alkyl; or

R and R together with the nitrogen atom to which they are joined form a nitrogen heterocycle having from five through seven ring atoms having one or two heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur and wherein at least one of said heteroatoms is nitrogen or R and R form a substituted nitrogen heterocycle having from five through seven ring atoms including one or two heteroatoms selected from the group of nitrogen, oxygen and sulfur and wherein at least one of said heteroatoms is nitrogen and having one or two substituents independently selected from the group of lower alkyl, and hydroxy(- lowerr alkyl);

Z is a substituent on the thiazole ring at either the 4- or 5-position selected from the group having the formulas:

O u mllL wherein R and R are independently selected from the group of hydrogen; alkyl having from one through 12 carbon atoms, cycloalkyl having from three through 12 carbon atoms; phenyl; lower phenylalkyl, substituted phenyl,

substituted lower phenylalkyl; terminally substituted alkyl group having from two through 12 carbon atoms having one substituted terminal carbon atom having from one through three substituents independently selected from the group of hydroxy, acyloxy having from two through 12 carbon atoms and alkoxy having from one through six carbon atoms; and groups having the formulas ---(Cl-l NR R or (CH ),,R wherein n is a whole integer of from one through four, R and R are independently selected from the group of hydrogen and alkyl groups having from one through four carbon atoms and R is cycloalkyl having from three through eight carbon atoms; and wherein when 2 is the group Ol R N- then R cannot be hydrogen;

R and R are independently selected from the group of hydrogen, lower alkyl, phenyl, lower phenylalkyl, substituted lower phenylalkyl or together with the carbon atom to which they are joined form a cycloalkyl having from five through seven carbon atoms;

R is hydrogen, lower alkyl, aryl or arylalkyl.

Also encompassed within the invention are pharmaceutically acceptable salts of the above compound formulas I and Ill.

The compounds of the invention have an asymmetric carbon atom in the propane side chain and thus exist as optical isomers. correspondingly the above formulas are intended to represent the respective individual and optical isomers as well as mixtures of such isomers and the individual isomers as well as mixtures thereof are encompassed within the invention. Where the compounds of the invention have l-positioned substituents, on the propane chain, which have assymmetric atoms, the compounds exhibit further optical activity with respect to such asymmetric atoms. Definitions As used herein above and below, the following terms shall have the following meaning unless expressly stated to the contrary. The term alkyl, or alkylene, refers to both straight and branched chain alkyl groups. Where primed numerals are used with respect to alkyl groups, branched alkyl groups are meant .with the primed numeals designating the position of lesser alkyl groups on the longer primary alkyl chain. Thus for example, the term 5'-methylhexyl refers to the group.

The term lower alkyl refers to both straight and branched chain alkyl groups having a total of from one through six carbon atoms and thus includes primary, secondary, and tertiary alkyl groups. Typical lower alkyls include, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-hexyl and the like. The term cycloalkyl refers to cyclic hydrocarbon groups having from three through 12 carbon atoms and preferably such groups having from 2 through 6 carbon atoms and wherein the double bond can be between any two adjacent carbon atoms. Typical lower alkenyl groups include, for example, vinyl, propenyl, and the like. The term alkoxy refers to groups having the formula R'O wherein R is alkyl and correspondingly the term lower alkoxy refers to the group having the formula RO- wherein R is loweralkyl. Typical alkoxy groups include, for example, methoxy, ethoxy, t-butoxy and the like. The term (lower alkoxy) lower alkyl or perhaps more correctly (lower alkoxy) lower alkylene refers to the group -R'OR" wherein R is lower alkylene and OR is lower alkoxy. The term hydroxy lower alkyl or hydroxy lower alkylene refers to groups having the formula HOR'-- wherein R is lower alkylene. Typical hydroxyalkyl or hydroxyalkylene groups include, for example; a-hydroxyethylene, B-hydroxypropylene, hydroxyisopropylene and the like. The term terminally substituted alkyl (or alkylene) refers to alkylene groups having from two through 12 carbon atoms in which the terminal carbon atom, or in the case of groups, such as t-butyl, which have more than one terminal carbon, wherein one of such terminal carbon atoms are substituted with from one through three substituents independently selected from the group of hydroxy, acyloxy and alkoxy. Typical terminally substituted alkyl groups include 2-hydroxy-ethylene, 3'-acetoxypropyl, B-methoxyethylene and the like. The term carboxy refers to the group COOH. The term halo refers to iodo, bromo, chloro and fluoro groups. The term acyl refers to acyl groups derived from carboxylic acids having from two through 12 carbon atoms such as acetyl, propionyl, butyryl, valeryl, isovaleryl, hexanoyl, heptanoyl, octanoyl, nonanoyl, undecanoyl, lauroyl, benzoyl, phenylacetyl, phenylpropionyl, 0-, m-, p-toluoyl, B-cyclopentylpropionyl, formyl and the like.

The term alkoxycarbonyl refers to groups having the formula wherein R is an alkyl group having from one through 11 carbon atoms. Typical alkoxycarbonyl groups thus include, for example, methoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, undecanoxycarbonyl and the like. The term acyloxy refers to groups derived from carboxylic acids having from two through l2 carbon atoms such as acetyloxy, propionyloxy, butyryloxy,

valeryloxy, isovaleryloxy, hexanoyloxy, heptanoyloxy, octanoyloxy, nonanoyloxy, undecanoyloxy, lauroyloxy, b enzoyloxy, phenylacetyloxy, phenylpropionyloxy, o-, m-,' p-toluoyloxy, B-cyclopentylpropionyloxy and the like.

The term aryl refers to phenyl or substituted phenyls as defined herein below. By the term alkylaryl is meant an alkyl substituted phenyl group having one or more alkyl substituents phenyl group having one or more alkyl substituents and having up to 12 carbon atoms as o-tolyl, m-tolyl, p-isopropylphenyl, 2,3- dimethylphenyl, 3,5-dimethylphenyl and the like. The term lower phenylalkyl refers to an alkyl group having from one through six carbon atoms and having a phenyl substituent. The term substituted lower phenylalkyl refers to an alkyl group having one through 6 carbon atoms and having a substituted phenyl (as defined herein) substituent. The term arylalkyl refers to the group of lower phenylalkyl and substituted lower phenylalkyl inclusive. The term substituted phenyl refers to phenyl groups which have one or two substituents independently selected from the group of hydroxy, lower alkyl, lower alkoxy or halo groups. Typical substituted phenyl groups include, for example, phydroxyphenyl, p-ethylphenyl, p-t-butoxyphenyl, pfluorophenyl, p-chlorophenyl and the corresponding ortho and meta isomers, 3,4-dimethoxyphenyl, 3- bromo-4-chlorophenyl and the like.

The term alkylamino refers to the group having the formula R'HN wherein R is alkyl and the term lower alkylamino refers to such groups wherein R is lower alkyl. The term dialkylamino refers to the group having the formula R 'R 'N wherein R and R are independently alkyl. Typical lower dialkylamino groups include, for example, dimethylamino, N-methyl-N- ethylamino, diethylamino, N-t-butyl-N-isopropylamino and the like.

The term aminocarbonyl or carbamoyl refers to the group having the formula The term substituted aminocarbonyl (e.g. alkylaminocarbonyl) or substituted carbamoyl refers to the group having the formula wherein R is as defined herein. Typical alkylaminocarbonyl or alkylcarbamoyl groups include, for example, methylaminocarbonyl or methylcarbamoyl; heptylaminocarbonyl or heptylcarbamoyl; nnonylaminocarbonyl or n-nonylcarbamoyl; and the like. The term disubstituted aminocarbonyl or disubstituted carbamoyl refers to groups having the formula wherein R and R are as defined herein. Typical dialkylaminocarbonyl or dialkylcarbamoyl groups include, for example, N-methyl-N-heptylaminocarbonyl or N-methyl-N-heptylcarbamoyl; diheptylaminocarbonyl or diheptylcarbamoyl, N-(n-nonyl)-N-(n-ocytyl)- aminocarbonyl or N-(n-nonyl)-N-(n-cytyl)- aminocarbamoyl and the like. The term hydroxyalkylaminocarbonyl or hydroxyalkylenaminocarbonyl or hydroxyalkylcarbamoyl refers to groups having the formula O ll HO-R,NC

wherein R, is an alkylene group having from two through twelve carbon atoms. The term alkoxyalkylaminocarbonyl or alkoxyalkylenaminocarbonylor alkoxyalkylcarbamoyl refers to groups having the formula 8 wherein R is as defined immediately above and R is alkyl. The term acyloxyalkylaminocarbonyl or acyloxyalkylcarbamoyl refers to groups having the formula O ll AcOR,-NC,

wherein R, is as defined above and AcO' is acyloxy as defined herein above.

The term formamido refers to the group having the formula The term N-substituted formamido (e.g. N- alkylformamido) refers to the groups having the formula I H N- wherein R is as defined herein. The term substituted amido (e.g. alkylarnido) or substituted carbonylamino (e.g. alkylcarbonylamino) or acylamino refer to the group having the formula wherein R is as defined herein. The term N-(substituted)substituted amido or N-(substituted)- substituted carbonylamino or N-substituted-acylamino refer to groups having the formula wherein R and R is as defined herein above. Typical groups having the formula v if,

wherein R is' as defined herein. The term N-substituted-substituted-oxy carbonylamino (e.g. N- alkyl-alkoxycarbonylamino; N- alkylphenoxycarbonylamino refers to groups having the formulas wherein R and R are as defined herein. Typical jf a ROCN- for N-methyl- N-heptyl-tand the like.

The term N-heterocycle alkyl or N-heterocycle alkyl ene refers to a lower alkylene group having an N- heterocyclic substituent as defined herein above. Such groups can be represented by the formula XR'- wherein X is N-heterocyclic and R is lower alkylene. With respect to the compounds of the invention, the morpholino, pyrrolidinyl, piperidino, piperazinyl and the group wherein R* is lower alkyl or lower hydroxyalkyl are the preferred heterocyclic groups.

The term pharmaceutically acceptable salts refers to pharmacetuically acceptable hydrogen-anion addition salts which do not adversely affect the pharmaceutical properties of the parent compounds. With respect to the addition salts, suitable inorganic anions include, for

example, chloride, bromide, iodide, sulfuate, phosphate, carbonate, nitrate, hydrocarbonate, sulfate, and the like. Suitable organic anions include, for example, acetate, benzoate, lactate, picrate, propionate, butyrate, valerate, tartrate, maleate, fumarate, citrate, succinate, tosylate, ascorbate, pamoate, nicotinate, adipate, glyconate and the like.

Typical illustrations of the compounds of formula I can be had, for example, herein below by reference to Examples 4-7, 9, l l, 12, 15-18. The preferred R and R substituents are those wherein one of R or R is hydrogen and the other is selected from the group of isopropyl; secbutyl; t-butyl; cyclopropyl; cyclopentyl; a-phenylethyl; ,B-hydroxyethyl; a-phenylpropyl; B-(3,4-dimethoxyphenyl)-ethyl); ,B-(4- hydroxyphenyl)-ethyl; a-methyl-B-(4-hydroxyphenyl)- ethyl; y-(4-hydroxyphenyl)-propyl; oz-methyl-y-(4- hydroxyphenyl)-propyl; a-methyl-y-phenylpropyl; and ,8-(4-aminocarbonylphenoxy)-ethyl. The preferred R and R substituent compounds of formula I are those wherein R is hydrogen and R is selected from the group of n-pentyl, n-hexyl, 3'-methylhexyl, lmethylhexyl, 4-ethylhexyl, 3'-propylhexyl, n-heptyl; n-octyl, cycloheptyl, cyclohexyl, ,B-cyclopentylethyl, 'y-cyclopentylpropyl, 4-cyclopentylbutyl, y-cyclohexylpropyl, benzyl, B-methoxyethyl, and 'y-dimethylaminopropyl and especially 5-methylhexyl and 4'- methylhexyl. The particularly preferred compounds of formula I are:

l-t-butylamino-3-( 5-3 methylhexylaminocarbonylthiazol-2-oxy )-2- propanol; l-isopropylamino-3-( 5-3 methylhexylaminocarbonylthiazol-Z-oxy)-2- propanol; l-[B-(4-aminocarbonylphenoxy)-ethylamino]-3-(5- 3 '-methylhexylaminocarbonylthiazol-Z-oxy )-2- propanol; l-t-butylamino-3-( 5-4- methylhexylaminocarbonylthiazol-2-oxy)-2- propanol;

1 S l-[ B-(4-aminocarbonylphenoxy)-ethylamino]-3-( 'y-cyclohexylpropoxycarbonylaminothiazol-Z-oxy 2-propanol.

Typical illustrations of the compounds of formula II can be had, for example, herein below by reference to Example 3. Further since the primary use of compounds of formula ll is as intermediates for the compounds of formula I, the preferred R and R substituents are the same as listed above for formula 1 and the particularly preferred compounds of formula I] are the precursors corresponding to the particularly preferred compounds of formula I as set forth herein above.

Typical illustrations of the compounds of formula III can be had, herein below, by reference to Examples and 13-18. The preferred R and R substituents for the compounds of formula III are the same as listed above for the compounds as formula I. The simpler R and R substituents are preferred (i.e. R and R are other than substituted ph'enyl) and the preferred compounds of formula lll are those wherein R and R are *each hydrogen or each methyl. The preferred R substituents are methyl, isopropyl, sec-butyl, t-butyl, cyclopropyl, cyclopentyl, a-phenylethyl, y-phenylpropyl, B-(3,4-dimethoxyphenyl)-ethyl, B-(4-hydroxyphenyl)-ethyl, oz-methyl-B-(4-hydroxyphenyl)-ethyl, 'y-(4-hydroxyphenyl)- butyl, oz-methyl-y-(B-hydroxyphenyl)-propyl, and a-methyl-B-phenylpropyl. The particularly preferred compounds of formula III are:

5-(5-3-methylhexylaminocarbonylthiazol-Z-oxy)- methylene-Ntbutyloxazolidine; 5-(5-3'-methylhexylaminocarbonylthiazol-2-oxy)- methylene-N-isopropyloxazolidine; 5-(5-4'-methylhexylaminocarbonylthiazol-Z-oxy)- methylene-N-t-butyloxazolidine; 5-(5-4-methylhexylaminocarbonylthiazol-Z-oxy)- methylene-N-isopropyloxazolidine; 5-(5-5-methylhexylaminocarbonylthiazol-Z-oxy)- methylene-N-t-butyloxazolidine; 5-(5-5'-methylhexylaminocarbonylthiazol2-oxy)- methylene-N-isopropyloxazolidine; 5-(5-4'-ethylhexylaminocarbonylthiazol-Z-oxy)- methylene-N-t-butyloxazolidine; 5-(5-4'-ethylhexylaminocarbonylthiazol-Z-oxy)- methylene N-isopropyloxazolidine; 5-(5-3-propylhexylaminocarbonylthiazol-Z-oxy)- methylene-N-t-butyloxazolidine; 5-(5-3-propylhexylaminocarbonylthiazol-2-oxy)- methylene-N-isopropyloxazolidine; 5-(5-n-heptylaminocarbonylthiazol-Z-oxy)- methyleneN-t-butyloxazolidine; 5-(5-n-heptylaminocarbonylthiazol-Z-oxy)- methylene-N-isopropyloxazolidine; 5(S-B-cyclopentylethylaminocarbonylthiazol-Z-oxy)- methylene-N-t-butyloxazolidine; S-(5-B-cyclopentylethylaminocarbonylthiazol-2- oxy)-methylene-N-isopropyloxazolidine; 5-(5-'y-cyclopentylpropylaminocarbonylthiazol-Z- oxy)methylene'N-t-butyloxazolidine; 5-(5-y-cyclopentylpropylaminocarbonylthiazol-2- oxy)-methylene-N-isopropyloxazolidine; 5-(5-4'-cyclopentylbutylaminocarbonylthiazol-2- oxy)-methylene-N-t-butyloxazolidine; 5-(5-4'-cyclopentylbutylaminocarbonylthiazol-Z- oxy)-rnethylene-N-isopropyloxazolidine; 5-(5-'y-cyclohexylpropylaminocarbonylthiazol-Z- oxy)-methylene-N-t-butyloxazolidine;

16 5-(5-'y-cyclohexylpropylaminocarbonylthiazol-2- oxy)-methylene-N-isopropyloxazolidine; and 5-(5-3'-methylhexylcarbonylaminothiazol-Z-oxy)- methylene'N-t-butyloxazolidine.

The corresponding 4 -position substituted thiazole position isomer corresponding to the particularly preferred 5-position compounds enumerated above with respect to formulas I, and Ill, are also preferred but generally the 5-position isomers have superior properties to the 4-p0 sition isomers.

The preferred pharmaceutically acceptable salts are hydrogen addition salts of chloride, bromide, sulfate, maleate, lactate, tartrate, succinate and especially chloride. Thus, the preferred salts are the preferred anion addition salts of formulas l and III and correspondingly the particularly preferred salts are the preferred hydrogen anion addition salts of the preferred and particularly preferred compounds of formulas l and III and especially the hydrochloride salts.

The compounds of the invention can be conveniently prepared by the following process, which can be represented by the following schematic overall reaction equation sequence:

17 wherein Y is alkyl or phenyl, and R, R and Z have the same meanings as set forth herein above.

Step 1 can be conveniently effected by treating the compound of formula A with a suitable organic or inorganic acid, preferably in a suitable inert solvent. Typically this threatment is conducted at temperatures in the range of about from to 65C and preferably about 25-30C, for about from 3 minutes to 18 hours and preferably about from 1 to 4 hours. However, temperatures, reaction times and mole ratios both above and below these ranges can also be used. Suitable inorganic acids which can be used include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and the like. Suitable organic acids which can be used include, for example, formic acid, oxalic acid, acetic acid, propionic acid, and the like. Suitable solvents which can be used include, for example, water, methanol, acetone, monoglyme, ether and the like. Good results are typically obtained by using aqueous formic acid solution.

Step 2 of the above process can be effected by treating the compound of formula B with a suitable phenyl sulfonyl chloride or bromide or alkyl sulfonyl chloride or bromide, in a suitable inert organic solvent in the presence of a base. The particular sulfonyl derivative used is largely immaterial since the sulfonyl substituent is split off during the next step. Thus, typically other phenyl sulfonyl chloride or bromide or alkyl sulfonyl chloride or bromide derivatives can also be used. Typically this treatment is conducted at temperatures in the range of from about 0 to 60C and preferably about from 0 to 25C for about from 5 minutes to 18 hours, preferably about from minutes to 45 minutes, using mole ratios in the range of about from 1.0 to 1.1 moles of sulfonyl derivatives per mole of compound of formula C. However, temperatures, treatment times, and mole ratios both above and below these ranges can also be used. Suitable phenyl sulfonyl chlorides or bromides, which can be used include, for example, benzene sulfonyl chloride, benzene sulfonyl bromide, or p-toluene sulfonyl chloride, p-ethyl benzene sulfonyl bromide, and the like. Suitable alkyl sulfonyl chlorides, and bromides, which can be used include, for example, methane sulfonyl chloride, methane sulfonyl bromide and the like. Suitable organic bases which can be used include, for example, pyridine, triethylamine or tertiary amines, and the like. Suitable solvents include methyl dichloride, diethyl ether, tetrahydrofuran and the like. Pyridine can be conveniently used as both the base and the solvent.

Step 3 can be conveniently effected by treating the compound of formula C with a strong base preferably in an inert organic solvent. Conveniently this treatment is conducted by adding a strong base directly to the product reaction mixture of step 2 without separation of the product of formula C from the reaction mixture. The treatment, can of course, also be applied to the isolated product of formula C. Typically this treatment is conducated at temperatures in the range of about from 0 to 100C, preferably about from 20 to 60C for from one-half hour to three hours, and preferably about from /2 hour to 1 hour. However, temperatures and reaction times both above and below these ranges can also be used. Suitable strong bases which can be used include, for example, alkali metal hydroxides such as, for example, sodium hydroxide, potassium hydroxide and the like, and alkali metal alkoxides such as, for example, sodium methoxide, potassium methoxide, and alkyl or aryl lithium such as butyl lithium, octyl lithium, phenyl lithium and the like. Suitable inert organic solvents include, for example, monoglyme, ethyl ether, benzene and the like. I

Step 4 can be conducted by treating the intermediate product of formula II, of the invention, with the desired R, R amine or amino derivative or N-heterocyclic derivative, including amines incorporated in cyclic systems. For example by treating the compound of formula II with an alcoholic solution of ammonia, the corresponding compounds of formula I wherein each of R and R is hydrogen is obtained. Similarly, treatment with a monosubstituted amine will yield the corresponding compound of formula I wherein one of R or R is the corresponding substituent and the other is hydrogen, and where a disubstituted amine is used, one of R or R will correspond to each of the amine substituents. Correspondingly, using a nitrogen heterocyclic such as, for example, piperidine; pyrrolidine; or morpholine will afford the corresponding N -piperidino; N -pyrrolidinyl; or N -morpholino compounds of formula I, respectively. Further, although optimum conditions and solvents will vary with the particular intermediate of formula II and ammonia or amino-type derivatives used, the treatment is typically conducted at temperatures in the range of about from 25 to C for about from 10 minutes to 18 hours. However, temperature ranges both above and below these can also be used. Suitable solvents which can be used include, for example, monoglyme, methanol, ethanol, pyridine and the like.

Also although not specifically stated, it should be understood, as would be apparent to one having ordinary skill in the art, that where the starting material for a given step has free hydroxy or free amino groups, which could interfere with the treatment, such groups are preferably protected with conventional labile ester or ether groups by procedures which are well within the scope of the art. For example, with respect to step 2, free hydroxy groups, other than the 1- and Z-hydroxy propane groups, are conveniently protected by treatment with acetic anhydride. The actate protecting group can then be conveniently removed, after the treatment of step 2, via treatment with a mild base.

Preferably, with the exception of step 3 which, as noted above, is conveniently conducted by direct addition to the product reaction mixture of the preceding step, the respective products of each step are isolated prior to their subsequent use as starting materials for the next succeeding step. Separation and isolation can be effected by any suitable separation or purification procedure such as, for example, evaporation, crystallization, chromatography, thin-layer chromatography, etc. Specific illustrations of typical separation and isolation procedures can be had by reference to the corresponding examples described herein below. However, other equivalent separation or isolation procedures could, of course, also be used. Where an isomer mixture of the product of formula I is obtained (for example, where racemic glycerol acetonide mixture has been used to prepare the starting material of formula A, the respective optically active and isomers can be resolved, if desired, by conventional procedures. For example, by reacting the compounds of formula I with an optically active acid which will yield a mixture of optical salts of the compounds of formula I are] acetonide isomer mixture will be used and thus typically the product will correspondingly be a racemic mixture. The starting materials of formula A" can be prepared according to known procedures such as, for example, described in l-lelv. Chim. Acta., p. 2057 (1954) and Helv. Chim. Acta., p. 1073 (1942). The starting materials of formula A and also the starting wherein X is chloro or bromo, R is lower alkyl and preferably ethyl.

Steps a and a of the above process can be effected by treating the respective thiazole compound of formula A or A" with glycerol acetonide in a suitable inert solvent, in the presence of an alkali metal hydride. Typically, this treatment is conducted at temperatures in the range of about from 20C to reflux for about from a few minutes to 20 hours, using mole ratios in the range of about 1 to 100 moles of glycerol acetonide per mole of compound A or A". However, temperatures, reaction times, and mole ratios both above and below can also be used. Suitable alkali metal hydrides which can be used include, for example, sodium hydride, potassium hydride, calcium hydride, lithium hydride and the like. Suitable inert organic solvents which can be used include, for example, monoglyme, tetrahydrofuran, diglyme, dimethylformamide, and the like. Also an excess of glycerol acetonide can be used as the solvent. Further by using the optically pure glycerol acetonide isomer (see .1. Biol. Chem., v. 128, p. 463 (1939)) or the optically pure glycerol acetonide isomer (see .1. Am. Chem. 500., v. 67, p. 944 (1945)), the corresponding or optically active isomer of formula A or A' is obtained. Correspondingly wherein a or isomer mixture of the glycerol acetonide is used, the product will similarly be a mixture of isomers. This optically active isomer relationship between the starting materials and products exist throughout all the steps of various processes described herein. Also typically and conveniently, a racemic glycmaterials of formula A" can be prepared according to the procedures set forth in the respective preparations described herein below or by obvious modifications of such procedures.

Step a can be conveniently effected by treating the compound of formula A with ammonia or an amine derivative having the desired R R groups. Typically, this treatment is conducted in a suitable inert organic solvent at temperatures in the range of about from 0 to 100C, preferably about from 20 to C for about from one to 48 hours, preferably about from 2 to 10 hours. Typically a 10-5O molar excess of the desired amine is used. Suitable amines which can be used include, for example, methylamine, ethylamine, 4- methylhexylamine, N-methyl-N-4-methylhexylamine, 5'-methylhexylamine, n-dodecylamine, cycloheptylamine, l2'-hydroxydodecylamine, hexylamine, heptylamine, dimethylamine, N-methyl-N-S methylhexylamine, N-heptyl-N-methylamine, y-cyclopentylpropylamine, B-cyclopentylethylamine, 4- cyclopentylbutylamine, dicycloheptylamine and the like. Suitable inert organic solvents which can be used include, for example, methanol, ethanol, glyme, and the like.

The starting materials of formula A where Z is series can also be prepared according to the following procedure represented by the following schematic overall reaction equation sequence:

wherein R is as defined herein above.

As shown above, the 4- or S-amino compounds of formula A** can be prepared from the corresponding 4- or S-nitro compounds of formula A** via hydrogenation. This can be conveniently effected by treating the nitro compound of formula A** in a suitable inert organic solvent with gaseous hydrogen in the presence of a suitable catalyst such as, for example, Raney nickel. This treatment is typically conducted at temperatures in the range of about from 30 to +30C, preferably about from 25 to 30C, for about from minutes to 16 hours and preferably about from one to three hours. Suitable solvents which can be used include, for

example, ethanol, methanol, ethyl acetate, tetrahydrofuran, and the like. Suitable hydrogenation catalysts which can be used include, for example, Raney nickel, palladium, and the like. The 5- or 4-nitrothiazole starting materials can be prepared by treating the corresponding 2-chloroor 2-bromo-5- or 4-nitrothiazole (Helv. Chim. Acta., v. 33, p. 306 (1950)) with glycerol acetonide as described above. Step b" of the above reaction sequence can be effected in two phases. In the first phase the 4- or S-amino compound of formula A* is treated with sodium hydride in an inert organic solvent containing a catalytic amount of t-butanol. Typically, this treatment is conducted at temperatures in the range of about from 0 to 20C, for about from one to 24 hours and preferably about from seven to eight hours. Best results are obtained by conducting this treatment under anhydrous conditions and preferably under an inert gaseous atmosphere. In the second phase the desired R -substituted chloroformate is then conveniently added to the reaction mixture, without separation of the intermediate product, and the mixture maintained at from about l0 to 80C, preferably at reflux, for from about /2 hour to 16 hours. Suitable alkyl chloroformates which can be used include, for example, 4-methylhexyl chloroformate, 5'-methylhexyl chloroformate, y-cyclopentylpropyl chloroformate, B-cyclohexylethyl chloroformate, n-heptyl chloroformate, and the like. Alternatively, step b' can be effected by treating the 4- or S-amino compound of formula A* with the desired R-substituted chloroformate in an inert organic basic solvent. Typically this treatment is conducted at temperatures in the range of about from 0 to C for about from one to 24 hours. The same range of alkyl chloroformates can be used in this treatment as above. Suitable basic solvents include, for example, pyridine, triethylamine and the like.

starting materials of formula A can also be prepared starting from the known R -carboxylic acid ethyl ester (Helv. Chim. Acta., v. 29, p. 1230 (l946)) according to the sequence represented by the following schematic reaction equations:

wherein R is lower alkyl, aryl or arylalkyl and R is as defined herein above for Z is Step c of the above reaction sequence can be effected by treating the above 2-chloro-4- or S-carboxylic acid or alkyl ester compound of formula A*** with hydrazine hydrate. Typically, this treatment is conveniently conducted at temperatures in the range of about from 0 to C, for about from 1 to six hours. Suitable inert organic solvents which can be used include, for example, methanol, ethanol, monoglyme, dimethylformamide and the like. Step c is effected in two steps, first by treating the 4- or 5-hydrazide product of step c (formula A**) with nitrous acid. The nitrous acid can be conveniently prepared by reacting sodium nitrite and cone. hydrochloric acid. The treatment (step c( 1)) is conveniently conducted at ambient temperatures although temperatures both above and below ambient can also be used. The resulting 4- or 5-azido-2- chlorothiazole is then heated (step c'(2)) at temperatures in the range of about from 60 to C under anhydrous conditions -in a suitable inert organic solvent; to give the 4- or 5-isocyanate of formula A*. Suitable inert organic solvents which can be used include, for example, benzene, toluene, xylene, diglyme, triglyme, and the like, and mixtures of such solvents.

Step 0 can be effected by treating the compounds of formula A* with an alcohol of the desired R group. Typically, and preferably, this treatment is conducted at temperatures in the range of about the reflux temperature of the system, for about from A to 5 hours. Suitable alcohols which can be used include, for example, heptanol, 5-methylhexanol, 4-methylhexanol, B-cyclohexylethanol, 'y-cyclohexylpropanol and the like. Alternatively, the treatment can be conducted in an inert organic solvent such as, for example, monoglyme, dioxane, benzene, and the like.

The starting material of formula A can then be prepared by treating the 2-chloro compounds of formula A with glycerol acetonide as described above.

Although the starting materials of formula A wherein Zis HNo

can be prepared according to conventional procedures I and rocedures described in the arent application Ser. IR" No. 289,730, filed Sept. 15, 1975, or by obvious modi- (87 E 1T Z Z fications thereof, much higher yields of this group of S starting materials can be obtained by using the procedure of Berkoz, Edwards and Fried described in US. (A) Pat. Ser. No. l,l94, filed on even date hereof (now US. Pat. No. 3,896,139) and which procedure can be represented by the following overall reaction sequence and description:

wherein X is chloro. bromo or iodo; and R and 10 R are as defined above.

CO Step 1'' of the above process can be conveniently efzfi Li 0 CH21:H$H2 fected by treating the 2,4-dibromothiazole or 2,5-

CH CH cumup od S o cH,-cH-oii,

ca, ci-r.

dibromothiazole starting material with glycerol acetonide, in a suitable inert organic solvent in the presence of an alkali metal hydride in the same manner as described herein above with respect to the preparation of other 4'- or 5'-position substituted thiazol-2-oxypropanediol 1,2-acetonides. The 2,5-dibromothiazole and 2,4-dibromothiazole are known compounds and can be prepared according to procedures described in Recueil des Travaux Chimiques des Pays Base, volume 73, page 325 (1964) and the 2,4-dibromothiazole in Bulletin de la Societe Chimique de France, page 1735 (1962), respectively.

Step 2" can be effected by treating the compound of formula D with an alkyl lithium reagent (preferably tor n-butyllithium) in a suitable inert organic solvent. Typically this treatment is conducted at temperatures in the range of about from l0 to l C, preferably about from to -C for about from 10 minutes to 2 hours, and preferably about from 15 minutes to 1 hour, using mole ratios in the range of about from two to three moles of alkyl lithium per mole of the compound of formula D. Best results are typically obtained by conducting the treatment under anhydrous conditions and preferably in the absence of air, e.g. by conducting the treatment under an inert gas such as nitrogen. Suitable inert organic solvents which can be used include, for example, tetrahydrofuran, hexane, diethyl ether, monoglyme, and mixtures of such solvents and the like.

Step 3" can be conveniently conducted in situ by bubbling anhydrous carbon dioxide through the reaction product solution of the compound of formula E. The carbon dioxide reaction is typically conducted at temperatures in the range of about from --78C to room temperature and since the rate of reaction will vary with the flow rate of carbon dioxide. the reaction is preferably monitored by thin-layer chromatography and allowed to proceed until the thin-layer chromatography reveals that 3-(thiazol-2-oxy)-propanediol acetonide derived from the starting material of formula E has been consumed.

Step 4 is also conveniently conducted in situ by adding an alkyl chloroformate directly to the reaction medium. Typically this step is conducted at temperatures in the range of about from 78C to room temperature for about from 1 to 6 hours. Suitable alkyl chloroformates which can be used include, for example, methyl chloroformate, ethyl chloroformate, isopropyl chloroformate, t-butyl chloroformate, n-butyl chloroformate and the like. Best results are typically obtained using ethyl chloroformate. Accordingly the above reaction sequence has been shown using ethyl chloroformate although other alkyl chloroformates could also be used. Also typically about from 1.1 to 1.5 moles of alkyl chloroformate is used per mole of compound of formula F.

Step is also conveniently conducted in situ by adding sodium azide, preferably as an aqueous solution, directly to the product reaction mixture of formula G. Typically this step is conducted at temperatures in the range of about from 0C to room temperature, preferably about from to 25C, for about from /2 hour to 6 hours, preferably about from /2 hour to 2 hours.

Step 6" is conveniently effected by adding the compound of formula H to an inert aromatic solvent, such as toluene, and heating the mixture at temperatures in the range of about from 100 to 110C, preferably about from l05108C, for about from /a hour to two hours. Also while best results are obtained using these conditions, temperatures and reaction times, both above and below these ranges could also be used. Also other inert solvents such as, for example, xylene and diglyme could also be used.

Step 7 can be conveniently effected by a Grignard type reaction by treating the isocyanate product of formula .1 with a Grignard reagent having the desired R- substituents. Typically this treatment is conducted at temperatures in the range of about from 78 to -l00C, preferably about -78C, for about from one minute to l /2 hour and preferably about from one minute to minutes. Typically the treatment is conducted in an inert solvent such as, for example, toluene, ether (diethyl), tetrahydrofuran, monoglyme and the like, or mixtures thereof. Suitable Grignard reagents which can be used are those having the general formula R MgX' wherein X is chloro, bromo or iodo and R is as defined herein, such Grignard reagents include, for example, methylmagnesium chloride, t-butylmagnesium bro-.

mide, 5-methylhexylmagnesium bromide; 4'-methylhexylmagnesium bromide; methylmagnesium iodide; butylmagnesium chloride; y-cyclopentylpropylmagnesium bromide; dodecylmagnesium bromide and the like. The Grignard reagent can be prepared according to known procedures, or obvious modifications thereof such as, for example, described in Fieser & Fieser, Reagents for Organic Synthesis, pages 415-424 (1967), John Wiley & Sons, Inc.

Where the R -substituted compounds are desired, step 8" can be conveniently conducted in two phases by first treating the R -substituted compound of formula A with a strong base such as butyllithium, tbutyllithium, sodium hydride, or potassium t-butoxide, in an inert organic solvent under anhydrous condition. Typically this treatment is conducted at temperatures in the range of about from 70 to -85C for about from 5 minutes to 2 hours, using about from 1 to 1.5 moles of strong base per mole of compound of formula A. Suitable inert organic solvents which can be used include, for example, tetrahydrofuran, diethyl ether and the like. The second phase is conducted in situ by adding the desired reagent having the formula R X wherein R and X are as defined above, preferably in an aprotic solvent (e.g. ether, tetrahydrofuran, monoglyme, dimethylformamide) to the product reaction mixture and then allowing the resulting mixture to warm to about room temperature. This phase is typically conducted at temperatures of about from 78 to 25C, conveniently room temperature, for about from /2 hour to 2 hours. Suitable R X' reagents include, for example, methyl iodide, ethyl bromide, phenyl chloride, propyl iodide,'5'-methylhexyl chloride and the like. The R X' reagents can be prepared according to conventional procedures, well known to the art, or by obvious modifications of such procedures.

The starting materials of formula A wherein Z is can be advantageously prepared according to the procedure described by Berkoz, Edwards and Fried, in the aforementioned US. application (Attorney File No. PA-648) via the following overall reaction sequence:

wherein R and R are as defined herein above.

Step 1" can be effected by treating the compound of formula J with an alcohol having the desired R group i.e. R OH. Although the treatment can be conducted without a solvent, the treatment is typically conducted in an inert-organic solvent such as, for example, toluene, since this simplifies isolation of the resulting product. The treatment is typically conducted at temperatures in the range of about from to C for about from /2 to 4 hours, preferably about one to two hours. Typically a stoichiometrical excess of alcohol is used, for example, a -20 mole equivalent excess can be conveniently used. Suitable R OH alcohols which can be used include, for example, S-methylhexyl alcohol; 4-methylhexyl alcohol; methanol; phenol; 'y-cyclophenylpropyl alcohol; dodecyl alcohol and the like.

Where the R -substituted compounds are desired, step 2" can be conveniently conducted in two phases by first treating the R -substituted compound of formula A with a strong alkali such as butyllithium, tbutyllithium, or sodium hydride, in an inert organic solvent under anhydrous condition. Typically this treatment is conducted at temperatures in the range of about from to C for about from /2 hour to 2 hours, using about from I to 1.5 moles of strong alkali per mole of compound of formula A. Suitable inert organic solvents which can be used include, for example, tetrahydrofuran, diethyl ether and the like. The second phase is conducted in situ by allowing the product reaction mixture to warm to about room temperature and then adding the desired reagent having the formula R X wherein R and X are as defined above, preferably in an aprotic solvent (e.g. ether, tetrahydrofuran, dimethylformamide, monoglyme, etc.). This phase is typically conducted at temperatures of about from 15 to 30C, conveniently room temperature, for about from /2 to 2 hours. Suitable R X reagents include, for example, methyl chloride, ethyl bromide, phenyl chloride, propyl iodo, 5-methylhexyl chloride and the like. The R X' reagents can be prepared according to conventional procedures, well known to the art, or by obvious modifications of such procedures.

The compounds of formula III can be prepared directly from the corresponding compounds of formula I:

wherein R R, R and Z are as defined herein above.

This treatment can be conveniently effected by treating the corresponding compound of formula I with a ketone or aldehyde having the desired R and R substituents, and aluminum isopropoxide. Typically this treatment is conducted at temperatures in the range of about from 20 to C for about from one to 48 hours using mole ratios in the range of about from one to moles of ketone and one to 10 moles of aluminum isopropoxide per mole of compound of formula 1.

Typically a substantial excess of ketone or aldehyde is used as the excess usually will function as an inert organic solvent. Suitable ketones which can be used include, for example, formaldehyde, acetone, cyclohexanone, cyclopentanone, cycloheptanone, and the like.

Also aluminum t-butoxide can be used in place of aluminum isopropoxide.

Alternatively the above treatment can be effected in the case of the 2-spirocycloalkyloxazolidine compounds, of formula Ill (i.e. R and R together with the carbon atom to which they are joined form a cycloal- 5 kyl), by treating the corresponding compound of formula I with a cycloalkanone having the desired cycloalkyl group, in an inert organic solvent in the presence of potassium carbonate. Typically this treatment is conducted at temperatures in the range of about from 20 to 100C for about from 48 to 72 hours, using mole ratios in the range of about from one to I50 moles of cycloalkanone per mole of compounds of formula I. Suitable cycloalkanones which can be used include, for example, cyclohexanone, cyclopentanone, cycloheptanone, and the like. In place of potassium carbonate, the following compounds can also be used; sodium carbonate, lithium carbonate, and the like.

The compounds of formula III, and of formula I, wherein Z is the group 20 25 and one of R or R is hydrogen and the other is hydrogen, lower alkyl, or arylalkyl, can also be prepared via the process of the invention, represented by the following schematic overall reaction equations:

OH (I) wherein R' is hydrogen, lower alkyl, aryl, or arylalkyl, X is chloro or bromo, and R, R, R R and R are as 5 defined herein above.

Step (I) of the above process can be effected by treating glycidol with ammonia or the desired monosubstituted amine. Typically, this treatment is conducted at temperatures in the range of about from 20C to reflux and preferably at reflux, for about from 0.5 to five hours. Frequently, as the reaction is exothermic and typically will occur at ambient temperature, the reaction can be conducted at reflux without supplying ex ternal heat. Also wherein anhydrous ammonia or vola tile amines are used, the reaction is typically conducted by passing the gaseous ammonia or subtracted amine through a solution of glycidol. Alternatively, suitable inert organic solvents can be used but, typically are unnecessary as glycidol itself is a liquid at room temperature in which the respective substituted amines are usually soluble. Suitable substituted amines which can be used include, for example, methylamine, ethylamine, propylamine, isopropylamine, n-butylamine, tbutylamine, phenylethylamine, p-methylbenzylamine and the like.

Step (2') can be effected by treating the product of step l of formula A, with an aldehyde or ketone in a suitable inert organic solvent such as, for example, ethanol. Typically, this treatment is conducted at temperatures in the range of about from 20C below reflux to reflux and preferably at reflux about from eight to 18 hours. Typically, formaldehyde is used in the form of an aqueous solution.

Step (3') is preferably conducted in two steps. In the initial phase the 5-hydroxymethyl-3-oxazolidine or 5-hydroxymethyl-substituted oxazolidine product of step (2') (i.e. formula B) is treated with an alkaline metal hydride, e.g. sodium hydride, in a suitable inert organic solvent. Typically, this treatment is conducted at temperatures in the range of about from 20 to 80C for about from minutes to five hours. Preferably this treatment is conducted under anhydrous conditions and preferably conducted in the absence of air, e.g. under an inert gas, e.g. nitrogen. Inert organic solvents which can be used include, for example, dimethylformamide, monoglyme, diglyme, and the like. The second phase of step (3) is conducted by treating the initial product reaction mixture with the desired substituted- 2-chloro or 2-bromothiazole. Typically, this treatment is conducted at temperatures in the range of about from 60 to 140C for about from 1 to 24 hours. Typically, the 2-halothiazole reagent is added to the reaction mixture in the form of a solution in a suitable inert organic solvent. Suitable inert organic solvents which can be used include, for example, dimethylformamide, monoglyme, diglyme, and the like. Also an excess of the oxazolidine reagent can typically be used as the solvent. Again preferably the second phase will also be conducted under anhydrous conditions and preferably conducted in an inert gas such as, for example, nitrogen.

Step (4') can be conveniently effected by simple acidic or basic hydrolysis of the intermediate of formula III. Thus, acid hydrolysis can be conveniently effected by treating the compound of formula III with a suitable organic acid such as, for example, acetic, formic, oxalic acid and the like or suitable acids such as, for example, hydrochloric, sulfuric, and the like. Preferably the hydrolysis is conducted under mildly acidic conditions. Similarly, basic hydrolysis can be conducted by treating the compound of formula III with a suitable base such as, for example, dilute sodium hydroxide, potassium hydroxide and the like. Preferably the hydrolysis can be conducted under mildly alkaline Again, as noted previously with respect to the first i described process of the invention, it should be understood that in each of the aforedescribed preparation and process steps, that where starting materials having free amino or free hydroxy groups which could interfere with the desired treatment are used, such starting materials are first protected with conventional labile ester or ether groups. And again, unless noted to the contrary, it is preferred that the respective products of each process step or preparation step, described herein above, be separated and/or isolated prior to its use as starting material for subsequent steps. Separation and isolation can be effected by any suitable purification procedure such as, for example, evaporation, crystallization, column chromatography, thin-layer chromatography, distillation, etc. Specific illustrations of typical separation and isolation procedures can be had by reference to the appropriate examples described herein below. However, other equivalent separation procedures could, of course, also be used. Also where an isomer mixture of the product of formula I or III is obtained (for example, wherein an isomeric mixture of glycerol acetonide has been used in steps 1 and 1 respectively), the respective optically active and isomers can be resolved by known procedures. Optimum resolution procedures can be obtained by routine trial and error procedures well within the scope of those skilled in the art.

The pharmaceutically acceptable acid addition salts of the compounds of formulas I and III can be prepared via neutralization of the parent compound, typically via neutralization of an amino moiety, with the desired acid. Other pharmaceutically acceptable addition salts can then be conveniently prepared from the neutralization addition salts via anion exchange with a suitable ion exchange resin in the desired anion form.

The compounds of formulas l and Ill, of the invention, are useful in the treatment and palliation of cardiovascular abnormalities in mammals. These compounds primarily achieve their therapeutic action by selectively blocking the cardiac B-adrenergic receptor sites and accordingly, because they are cardiac selective, they can also be applied to treat cardiac abnormalities in patients suffering from asthma or chronic obstructive lung disease. The compounds are especially useful in the treatment or palliation of cardiac arryhthmias, angina pectoris, hypertrophic subaortic stenosis, pheochromocytome, thyrotoxicosis, hyperkinetic syndromes, tetralogy of Fallot, mitral stenosis with tachycardia, general ischemic conditions, and hypertension founded on elevated cardiac outputs due to a hyperadrenergic state. The compounds are active, both in the treatment or palliation of acute attacks of such cardiac disorders, and further can be applied prophylactically to prevent or reduce the frequency of such attacks. This prophylactic action is particularly desirable in reducing the frequency of attacks of angina pectoris, since the medication (i.e. nitroglycerin) presently commonly used in the treatment of angina pectoris has no recognized prophylactic action.

Additional information concerning the use, action and determination of B-blockers can be obtained by reference to the literature such as, for example, Dotlery et al, Clinical Pharmacology and Therapeutics, volume 10, No. 6, 765-797 and the references cited therein.

The compounds of formulas l and Ill can be administered in a wide variety of dosage forms, either alone or in combination with other pharmaceutically compatible medicaments, in the form of pharmaceutical compositions suited for oral or parenteral administration. The compounds are typically administered as pharmaceutical compositions consisting essentially of the pharmaceutically acceptable salts of the compounds of formula 1 and/or 11] and a pharmaceutical carrier. The pharmaceutical carrier can be either a solid material or liquid, in which the compound is dissolved, dispersed or suspended, and can optionally contain small amounts of preservatives and/or pl-l-buffering agents. Suitable preservatives which can be used include, for example, benzyl alcohol and the like. Suitable buffering agents include, for example, sodium acetate and pharmaceutical phosphate salts and the like.

The liquid compositions can, for example, be in the form of solutions, emulsions, suspensions, syrups or elixirs and optionally can contain small quantities of preservatives and/or buffering agents.

The solid compositions can take the form of tablets, powders, capsules, pills or the like, preferably in unit dosage forms for simple administration or precise dosages. Suitable solid carriers include, for example, pharmaceutical grades of starch, lactose, sodium saccharin, sodium bisulfite and the like. i

The compounds of this invention are typically administered in dosages of about from 0.1 to 5 mg. per kg. of body weight. The precise effective dosage will, of course, vary depending upon the mode of administration, the condition being treated and the host. Preferably, the compounds are administered orally, either as solid compositions, e.g. tablets, or liquids as described herein above.

A further understanding of the invention can be had from the following non-limiting Preparations and Examples. Also as used herein above and below unless expressly stated to the contrary, all temperatures and temperature ranges refer to the Centigrade system and the terms ambient or room tmperature refer to about 20C. The term percent or refers to weight percent. The term equivalent refers to a quantity of reagent equal in moles to the moles of the preceding or succeeding reactant recited in that Preparation or Example in terms of moles or finite weight or volume. Also unless expressly stated to the contrary, racemic mixtures are used as starting materials and correspondingly racemic mixtures are obtained as products and where necessary, preparations and examples are repeated to provide sufficient quantities of starting materials for subsequent preparations and examples.

PREPARATION l 2-Bromo-5-alkoxycarbonylthiazole A mixture containing 272 g. of methyl chloroacetate and 158 g. of methyl formate in 600 ml. of toluene is cooled to C. A total of 143 g. of sodium methoxide is added portionwise, maintaining the temperature of the mixture below 5C, with rapid stirring. The mixture is then stirred for an additional four hours at 0C and one liter of water then added yielding a two phase liquid-liquid mixture. The toluene layer is decanted off and the aqueous layer is then washed with ethyl ether and neutralized with dilute aqueous hydrochloric acid and extracted with ethyl ether. The ethyl ether extracts are combined, dried over magnesium sulfate and then evaporated yielding the oil residue of methyl chloroformyl acetate. 210 Grams of thiourea in 1,500 ml. of ethanol is then added to the residue and refluxed for 18 hours. The ethanol solvent is then distilled off and one liter of water added to the concentrate. The aqueous mixture is then filtered and the filtrate made slightly basic by the addition of dilute aqueous ammonium hydroxide yielding a precipitate which is then recovered by filtration, washed with water, and dried, under vacuum, for 18 hours at C yielding 2-amino-5- methoxycarbonylthiazole.

A mixture containing 100 g. of amyl nitrate and 600 ml. of bromoform is warmed to 70C and then a total of 100 g. of 2-amino-S-methoxycarbonylthiazole is added portionwise with rapid stirring while maintaining the temperature at about -l00C. The mixture is then stirred for an additional ten minutes at this temperature and then the bromoform is distilled off under vacuum. The residue is chromatographed on silica gel yielding 2-bromo-5-methoxycarbonylthiazole.

Similarly, 2-bromo-5-ethoxycarbonylthiazole is prepared by following the same procedure but using ethyl chloroacetate and sodium ethoxide in place of methylchloroacetate and sodium methoxide.

2-Bromo-4-methoxycarbonylthiazol and 2-bromo-4- ethoxycarbonylthiazole are respectively prepared by following the procedure described in Helv. Chim. Acta., v. 25, p. 1432 (1942); ibid., v. 28, 362 (1945) and ibid., v. 27, p. 1432 (1944).

PREPARATION 2 2-Bromo-5-substituted aminocarbonylthiazole A mixture containing 10 g. of 2-bromo-5- methoxycarbonylthiazole, 10 ml. of 5'- methylhexylamine, 12 ml. of water and 50 ml. of methanol is stirred for 18 hours at room temperature. The mixture is then evaporated to remove methanol and poured into 500 ml. of ethyl acetate, which is then washed three times with water, then dried over magnesium sulfate and evaporated to dryness. The residue is then redissolved and recrystallized from ethyl acetate affording 2-bromo-5-(5-methylhexylaminocarbonyl)- thiazole.

Similarly, by following the same procedure but respectively replacing 5'-methylhexylamine with 40'- methylhexylamine, 3-methylhexylamine, 4'- ethylhexylamine, 3'-propylhexyl, cyclopentylamine, B-cyclopentylethyl, 'y-cyclopentylpropyl, 4- cycl pentylbutylamine, 'y-cyclohexylpropyl, nheptylamine, cycloheptylamine, n-octylamine, nnonylamine, n-dodecylamine, 7-hydroxy-nheptylamine, 9-acetoxy-n-nonylamine, B-methoxyethylamine, di('y-cyclopentylpropyl)amine, di(ndodecyl)amine, hexylamine, methylamine, dimethylamine, isopropylamine, aqueous ammonia, and benzylamine the following compounds are respectively prepared:

2-b romo-5-(4-methylhexylaminocarbonyl)-thiazole; 2-bromo-5-(3-methylhexylaminocarbonyl)-thiazole; 2-bromo-5-(4'-ethylhexylaminocarbonyl)-thiazole; 2-bromo-5-(3'propylhexylaminocarbonyl)-thiazole; 2-bromo-5-cyclopentylaminocarbonylthiazole; 2-bromo-5-(B-cyclopentylethylaminocarbonyl)- thiazole; 2-bromo-5-(y-cyclopentylpropylaminocarbonyl)- thiazole;

il-bromo-S-n-heptylaminocarbonylthiazole; 2-bromo-5-(4'-cyclopentylbutylaminocarbonyl)- thiazole; 2-bromo-5-('y-cyclohexylpropylaminocarbonyl)- thiazole; bromo-S-cycloheptylaminocarbonylthiazole; bromo-S-octylaminocarbonylthiazole; bromo-S-nonylaminnocarbonylthiazole; bromo-S-dodecylaminocarbonylthiazole; -bromo-5-(7-hydroxyheptylaminocarbonyl)- thiazole; l2-bromo-5-(9'-acetoxynonylaminocarbonyl)- thiazole; 2-bromo-5-(B-methoxyethylaminocarbonyl)- thiazole;

2-bromo-5-di-(y-cyclopentylpropyD- .aminocarbonylthiazole; 2-bromo-5-di-(n-dodecyl)-aminocarbonylthia2ole;

I2-bromo-5-hexylaminocarbonylthiazole;

2-bromo-5-methylaminocarbonylthiazole;

Z-bromo-5-dimethylaminocarbonylthiazole;

Z-bromo-5-isopropylaminocarbonylthiazole;

2-bromo-S-aminocarbonylthiazole; and

Z-bromo-5-benzylaminocarbonylthiazole.

Similarly, by following the same procedure but using 3-bromo-4-methoxycarbonylthiazole in place of 2- bromo-S-methoxycarbonylthiazole, the corresponding l-position isomers of each of the above products is respectively prepared.

PREPARATION 3 2-Bromo-S-carboxythiazole A mixture containing 10 g. of 2-bromo-5- methoxycarbonylthiazole, 100 ml. of 10% aqueous sodium hydroxide and 200 ml. of methanol is stirred at C for five minutes. The methanol is distilled off in vacuo and the resulting concentrate extracted twice with ethyl acetate. The remaining aqueous phase is acidified by the careful addition of dilute aqueous hydrochloric acid resulting in the formation of a precipitate which is then recovered by filtration and dried under vacuum yielding 2-bromo 5-carboxythiazole.

Similarly, 2-bromo-4-carboxylthiazole is prepared according to the same procedure but using 2-bromo4- methoxycarbonylthiazole in place of 2-bromo-5- methoxyearbonylthiazole.

PREPARATION 4 Z-Bromo-S-substituted aminocarbonylthiazole.

A mixture containing 6 g. of 2-bromo-5- carboxylthiazole, 3 ml. thionyl chloride, and 0.5 ml. of dimethylformamide in 150 ml. of ethyl acetate is refluxed for 30 minutes and then evaporated to remove the ethyl acetate solvent. The resulting residue is dissolved in 100 ml. of chloroform, then cooled to about 0C. A mixture containing 10 ml. of t-butylamine in .l00 ml. of chloroform is then added with stirring and the ensuing mixture warmed to 0C, washed twice with water and then dried over magnesium sulfate and evaporated to dryness affording a solid residue of 2-bromo- 5-t-butylaminocarbonylthiazole.

Similarly, 2-bromo-4-t-butylaminocarbonylthiazole is prepared by following the same procedure but using I2-btomo-4-carbonylthiazole in place of the 5-position.

isomer. Similarly, by replacing t-butylamine with the amine reagents set forth in Preparation 2, the corresponding 2-bromo-4- and 5-substituted aminocarbonylthiazoles are respectively prepared.

PREPARATION 5 3-(5-Bromothiazol-2-oxy)-propanediol acetonide In this preparation sodium hydride (l8 g., 56 wt. dispersion in oil) is washed with n-hexane, and the hexane is replaced with monoglyme (100 ml. To this mixture is added a solution of glycerol acetonide (44.5 g.) in monoglyme (200 ml.) under an atmosphere of nitrogen. After 15 minutes, 2,5-dibromothiazole (32 g.) is added, and the mixture is refluxed for 1.25 hours. The reaction mixture is then cooled, diluted with ether and filtered. The filtrate is washed with saturated aqueous sodium chloride twice, dried and concentrated by evaporation. Fractional distillation yields 3-(5- bromothiazol-2-oxy)-propanediol 1,2-acetonide.

Similarly 3-(4-bromothiazol-2-oxy)-propanediol 1,2- acetonide is prepared by following the same procedure but replacing 2,5-dibromothiazole with 2,4- dibromothiazole.

EXAMPLE Av 3-( 5-Azidocarbonylthiazol-2-oxy)-propanediol 1,2-

acetonide.

Examples A-E, illustrate the preparation of acetonide intermediates according to the procedure of Berkoz, Edwards and Fried, described in U.S. Ser. No. 451,194, filed on even date herewith (now U.S. Pat. No. 3,896,139).

In this example 150 ml. of B-butyllithium, in hexane, solution (each ml. of solution contains 100 mg. of butyllithium) is cooled to 78C and then added to a solution containing 60 g. of 3-(5-bromothiazol-2-oxy)- propanediol 1,2-acetonide in 200 ml. of anhydrous tetrahydrofuran at 78C under a nitrogen atmosphere. The resultant mixture is maintained at 78C for 15 minutes affording 3-(5-lithiothiazol-2-oxy)- propanediol 1,2-acetonide. A stream of anhydrous carbon dioxide is then passed through the solution. The mixture is periodically sampled and monitored by thinlayer chromotography and the carbon dioxide treatment continued until all of the starting material is consumed (about 2 hours). Thirty grams of ethyl chloroformate is then added to the reaction mixture and the temperature of the resulting mixture allowed to rise to room temperature and allowed to stand at room temperature for three hours. An aqueous solution containing 50 g. of sodium azide in ml. of water is then added and the resulting mixture stirred vigorously for 50 minutes. The tetrahydrofuran solvent is then distilled off at 50C and the resulting residue is then washed with diethyl ether and then with water affording a crude residue of 3-(5-azidocarbonylthiazol-2- oxy)-propanediol 1,2-acetonide. The crude residue is then further purified by chromatography over aluminum oxide (neutral, activity III) eluting with a gradient system of 3,000 ml. of hexane and 3,000 ml. of benzene.

Similarly by following the same procedure but using 3-(4-bromothiazol-2-oxy)-propanediol l,2-acetonide as the starting material, the corresponding 3-(4- azidocarbonylthiazol-Z-oxy)-propanediol 1,2- acetonide is prepared.

EXAMPLE B 3-[5-y-cyclopenetylpropylcarbonylaminothiazol-2- oxy]-propanediol 1,2-acetonide.

In this example a Grignard reagent is prepared by adding 5 g. of y-cyclopentylpropyl bromide to a suspension of 700 mg. of magnesium in 100 ml. of anhydrous ethyl ether at room temperature under an argon atmosphere. The resulting exothermic reaction is allowed to go to completion affording a liquid mixture containing the Grignard reagent 'y-cyclopentylpropylmagnesium bromide, which is then cooled and maintained at 78C.

3-( lsocyanatothiazol-Z-oxy )-propanediol l,2- acetonide is prepared by adding 5.5 g. of 3-(5- azidocarbonylthiazol-2-oxy)-propanediol 1,2- acetonide to 100 ml. of anhydrous toluene. The mixture is then heated, under an argon atmosphere, at 108C for 40 minutes. The resulting mixture is then cooled to 78C and added to the 'y-cyclopentylpropylmagnesium bromide diethyl ether solution previously prepared. The combined reaction mixture is allowed to react for one minute and then 2 ml. of water is added and the temperature of the mixture allowed to rise to room temperature. The resulting product mixture is then filtered, dried over sodium sulfate, filtered and evaporated to dryness affording a residue which is then further purified by plate chromatography eluting with a system of 5% methanol-95% chloroform yielding 3- (5-'y-cyclopentylpropylcarbonylaminothiazol-2-oxy)- propanediol l,2-acetonide.

Similarly by following the same procedure but substituting the appropriate Grignard reagents, the following compounds are respectively prepared:

3-(5-5'methylhexylcarbonylaminothiazol-Z-oxy)- propanediol l,2-acetonide; 3-((53methylhexylcarbonylaminothiazol-2-oxy)- propanediol l,2-acetonide; 3-(54methylhexylcarbonylaminothiazol-2-0xy)- propanediol l,2-acetonide; 3-(5-4ethylhexylcarbonylaminothiazol-Z-oxy)- propanediol l,2-acetonide; 3-(5-3propylhexylcarbonylaminothiazol-2oxy)- propanediol l,2-acetonide; 3-(5nheptylcarbonylaminothiazol-2-oxy)- propanediol l,2-acetonide; 3-5B-cyclopentylethylcarbonylaminothiazol-Z-oxy)- propanediol 1,2-acetonide; 3-(5-4cyclopentylbutylcarbonylaminothiazol-2- oxy)-propanediol l,2-acetonide; 3-(S-y-cyclohexylpropylcarbonylaminothiazol-2- oxy)-propanediol l,2-acetonide; 3-(5methylcarbonylaminothiazol-2-oxy)-2- propanediol l,2-acetonide; 3-(5t-butylcarbonylaminothiazol'2-oxy)- propanediol l,2-acetonide; 3-(5n-hexylcarbonylaminothiazol-Z-oxy)- propanediol l,2-acetonide; and 3-(5benzylcarbonylaminothiazol-Z-oxy) propanediol l,2-acetonide.

Similarly by following the same procedure but using the corresponding 4-position isomers, the corresponding 4-position isomer is respectively prepared.

EXAMPLE C 3-( S-N -methyl-'ycyclopentylpropylcarbonylaminothiazol-2oxy propanediol l,2-acetonide.

In this example 1.1 equivalent of butyllithium in 25 ml. of hexane is added to a solution containing 0.5 g. of 3-[57-cyclopentylpropylcarbonylaminothiazol-2- oxy]propanediol 1,2-acetonide in 25 ml. of tetrahydrofuran at 78C. Ten equivalents of methyl iodide is then added and the resulting mixture allowed to stand for 50 minutes and then refluxed for 5 hours. The mixture is then filtered, dried over sodium sulfate and evaporated to dryness affording a crude residue of 3- [5-N-methyl-'ycyclopentylpropylcarbonylaminothiazol-Z-oxy]- propanediol l,2-acetonide which is then further purified by thin-layer chromatography.

Similarly by following the same procedure using the products of Example B as starting materials, the corresponding N-methyl derivatives of the products of Example B are respectively prepared.

Similarly by following the same procedure but using in place of methyl chloride, the following compounds 5'-methylhexyl chloride, 4'-methylhexylbromide, phenyl bromide, y-cyclopentylpropyl bromide, and ethyl iodo, the corresponding N'-methylhexyl, N-phenyl, N-y-cyclpentylpropyl and N-ethyl derivatives are respectively prepared.

EXAMPLE D 3-( 5y-cyclopentylpropoxycarbonylaminothiazol-2- oxy)-propanediol l,2-acetonide.

In this example 5.2 g. of 3-(5-azidocarbonylthiazol- 2-oxy)-propanediol l,2-acetonide is added to a mixture of ml. of anhydrous toluene and 4 ml. of y-cyclopentylpropanol. The resulting mixture is heated for 1 hour at 107C and then the solvent distilled off under reduced pressure affording a crude residue of 3-(5-'ycyclopentylpropoxycarbonylaminothiazole-2-oxy)-propanediol l,2-acetonide which then further purified by chromatography.

Similarly by following the same procedures using the corresponding substituted alcohol starting materials, the following compounds are respectively prepared:

3-( 5-5 'methylhexoxycarbonylaminothiazol-2-oxy)- propanediol 1,2-acetonide; 3-(54methylhexoxycarbonylaminothiazol-Z-oxy)- propanediol l,2-acetonide; 3-(5-3-methylhexoxycarbonylaminothiazol-2-oxy)- propanediol l,2-acetonide; 3-(5-4'-methylhexoxycarbonylaminothiazol- 2-oxy)- propanediol l,2-acetonide; 3-(5-4-ethylhexoxycarbonylaminothiazol-2oxy)- propanediol l,2-acetonide; 3-(5-3propylhexoxycarbonylaminothiazol-2-oxy)- propanediol l,2-acetonide; 3-(S-nheptoxycarbonylaminothiazol-Z-oxy)-2- propanediol l,2-acetonide; 3-(5y-cyclopentylpropoxycarbonylaminothiazol-2- oxy)-propanediol l,2-acetonide; 3-(5y-cyclohexylpropoxycarbonylaminothiazol-2- oxy)-propanediol l,2acetonide; 3-(5-methoxycarbonylaminothiazol-2-oxy)- propanediol l,2-acetonide; 3-(5t-butoxycarbonylaminothiazol-2-oxy)- propanediol l,2-acetonide; 3-( 5nhexoxycarbonylaminothiazol-2-oxy propanediol l,2acetonide; and 3-(5benzyloxycarbonylaminothiazol2-oxy)- propanediol.

Similarly by following the same procedure but using the 4-position azidocarbonylthiazole isomer as starting material, the corresponding 4-position isomers of the above compounds are respectively prepared.

EXAMPLE E 3-( N '-methyl-y-cyclopentylpropoxycarbonylamino]-thiazol-2-oxy)-propanediol l,2-acetonide.

in this example 1.1 equivalents of butyllithium in hexane is added to a solution containing 500 mg. of 3- (5-7-cyclopentylpropoxycarbonylaminothiazol-Z-oxy)- propanediol l,2-acetonide in 25 ml. of tetrahydrofuran at --7 8C. 10 equivalents of methyl iodide is then added and the resulting mixture allowed to stand for 50 minutes and then heated at reflux for 5 hours. The mixture is then filtered, dried over sodium sulfate and evaporated to dryness affording a crude residue of 3-(5-[N- methyl-'y-cyclopentylpropoxycarbonylamino]-thiazol-2-oxy)-propanediol l,2-acetonide which is then further purified by chromatography.

Similarly by following the same procedure using the products of Example D as starting materials, the corresponding N'-methyl derivatives of the products of Example D are respectively prepared.

Similarly by following the same procedure but using in place of methyl chloride, the following compounds 5'-methylhexyl chloride, 4-methylhexyl bromide, phenyl bromide, y-cyclopentylpropyl bromide, and ethyl iodo, the corresponding N-methylhexyl, N-phenyl, N'-y-cyclopentylpropyl, and N'-ethyl derivatives are respectively prepared.

EXAMPLE F 3-( S-Formamidothiazol-Z-oxy )-prop anediol l,2-acetonide.

A solution containing 0.5 g. of 3-(5- isocyanatothiazol-Z-oxy)-propanediol l,2-acetonide in ml. of 99.1% aqueous formic acid is heated at 80C and monitored until thin-layer chromatographic analysis shows formation of the formyl derivative to be complete. The solvents are then removed by lyophilization and the residue dissolved in methylene dichloride. The methylene dichloride solution is washed with aqueous 1% sodium hydroxide solution and water, dried over sodium sulfate and evaporated to dryness yielding 3-(5- formamidothiazol-Z-oxy)-propanediol. Similarly, 3-(4- formamidothiazol-Z-oxy)-propanediol is prepared by the same procedure but using 3-(4- isocyanatothiazol-Z-oxy)-propanediol l,2-acetonide as starting material.

EXAMPLE 1 in this example 10 g. of 2-bromo-5- ethoxycarbonylthiazole is stirred in 100 ml. of anhydrous tetrahydrofuran, under a nitrogen atmosphere, and then 8.4 g. of a glycerol acetonide is added dropwise with stirring and the stirring continued until the solution is complete. The mixture is then cooled to 5C and 2.24 g. of sodium hydride (50% dispersion containing 2.24 g. of sodium hydride in mineral oil) in 100 ml. of anhydrous tetrahydrofuran is added and the resulting mixture allowed to warm to room temperature and allowed to stand for one half hour. The mixture is cooled to l0C, resulting in the formation of a precipitate, and then poured into 200 ml; of ethyl acetate. The ethyl acetate mixture is washed three times with water, then dried over magnesium sulfate and evaporated to an oil which is then chromatographed on silica gel affording 3-(S-ethoxycarbonylthiazol-Z-oxy)- propanediol l,2-acetonide.

EXAMPLE 1A This example illustrates methods according to the invention for preparing the intermediates of formula A wherein Z is O RR N 20 In this example a methanol solution containing 5 g. of

3-(5-ethoxycarbonylthiazol-2-oxy)-propanediol l,2- acetonide; 20 ml. of water and ml. of 4'- methylhexylamine and sufficient methanol to make the mixture homogeneous is stirred at room temperature 25 for 18 hours, and then poured into 500 ml. of ethyl acetate. The ethyl acetate mixture is washed three times with water, dired over magnesium sulfate and evaporated to dryness affording a residue of 3-(5-4-methylhexylaminocarbonylthiazol-Z-oxy)-propanediol l,2-

acetonide which is then further purified by recrystallization using an ethyl-hexane mixture.

Similarly, by following the same procedure but respectively replacing 4'-methylhexylamine with the amines enumerated in Column A, the corresponding products of Column B are respectively prepared:

COLUMN A 3-methylhexylamine;

5 '-methylhexylamine; 4'-ethylhexylamine;

3 '-propylhexylamine; n-heptylamine; B-cyclopentylethylamine; 'y-cyclopentylpropylamine; 4'-cyclopentylbutylamine; 'y-cyclohexylpropylamine;

5 -methyl-2'-methylhexylamine; 4'-methyl-l '-methylhexylamine; 'y-dimethylaminopropylamine; 6'-methylheptylamine;

5 '-methylheptylamine;

N-(5 '-methylhexyl)-N-methylamine; N-(4-methylhexyl )-N-methylamine; 6'-ethoxy-n-hexylamine, n-hexylamine;

methylamine;

dimethylamine;

t-butylamine;

aqueous ammonia; and benzylamine.

COLUMN B 

1. A COMPOUND SELECTED FROM THE GROUP HAVING THE FORMULAA:
 2. The compound of claim 1 wherein said acyloxy is selected from the group consisting of acetyloxy, propionyloxy, butyryloxy, valeryloxy, isovaleryloxy, hexanoyloxy, heptanoyloxy, octanoyloxy, nonanoyloxy, undecanoyloxy, lauroyloxy, benzoyloxy, phenylacetyloxy, phenylpropionyloxy, o-toluoyloxy, m-toluoyloxy, p-toluoyloxy, and Beta -cyclopentylpropionyloxy.
 3. The compound of claim 1 wherein R3 is hydrogen.
 4. The compound of claim 1 wherein one of R1 or R2 is hydrogen.
 5. The compound of claim 1 wherein Z has the formula
 6. The compound of claim 1 wherein said compound is selected from the group having the formula:
 7. The compound of claim 6 wherein R3 is hydrogen.
 8. The compound of claim 6 wherein one of R1 or R2 is hydrogen.
 9. The compound of claim 6 wherein R4 is selected from the group consisting of 3''-methylhexyl, 1''-methylhexyl, 4''-ethylhexyl, 3''-propylhexyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, cycloheptyl, cyclohexyl, Beta -cyclopentylethyl, gamma -cyclopentylpropyl, 4''-cyclopentylbutyl, gamma -cyclohexylpropyl, 4''-methylhexyl, 5''-methylhexyl, Beta -methoxyethyl and gamma -dimethylaminopropyl.
 10. The compound of claim 9 wherein R3 is hydrogen.
 11. The compound of claim 9 wherein R4 is selected from the group consisting of 4''-methylhexyl and 5''-methylhexyl.
 12. The compound of claim 6 wherein one of R1 or R2 is hydrogen and the other is selected from the group of isopropyl, sec-butyl, t-butyl, cyclopropyl, cyclopentyl, Alpha -phenylethyl, Alpha -phenylpropyl, Beta -(3,4-dimethoxyphenyl)-ethyl, Beta -(4-hydroxyphenyl)-ethyl, Alpha -methyl- Beta -(4-hydroxyphenyl)-ethyl; gamma -(4-hydroxyphenyl)-propyl; Alpha -methyl- gamma -(4-hydroxyphenyl)-propyl; Alpha -methyl- gamma -phenylpropyl, Beta -(4-aminocarbonylphenoxy)-ethyl and Beta -hydroxyethyl.
 13. The compound of claim 12 wherein one of R1 or R2 is hydrogen and the other is selected from the group consisting of isopropyl, t-butyl and Beta -(4-aminocarbonylphenoxy)-ethyl.
 14. The compound of claim 12 wherein R3 is hydrogen and R4 is selected from the group consisting of 3''-methylhexyl, 1''-methylhexyl, 4''-ethylhexyl, 3''-propylhexyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, cycloheptyl, cyclohexyl, Beta -cyclopentylethyl, gamma -cyclopentylpropyl, 4''-cyclopentylbutyl, gamma -cyclohexylpropyl, 4''-methylhexyl, 5''-methylhexyl, Beta -methoxyethyl and gamma -dimethylaminopropyl.
 15. The compound of claim 14 wherein one of R1 or R2 is hydrogen and the other is selected from the group consisting of isopropyl, t-butyl and Beta -(4-aminocarbonylphenoxy)-ethyl.
 16. The compound of claim 15 wherein R4 is selected from the group consisting of 5''-methylhexyl, 4''-methylhexyl, n-heptyl and n-hexyl.
 17. The compound of claim 16 wherein said compound is selected from the group consisting of 1-t-butylamino-3-(5-5''-methylhexylaminocarbonylthiazol-2-oxy)-2-propanol and pharmaceutically acceptable salts thereof.
 18. The compound of claim 16 wherein said compound is selected from the group consisting of 1-isopropylamino-3-(5-5''-methylhexylaminocarbonylthiazol-2-oxy)-2-propanol and pharmaceutically acceptable salts thereof.
 19. The compound of claim 16 wherein said compound is selected from the group consisting of 11( Beta -(4-amioncarbonylphenoxy)-ethylamino)-3-(5-5'' -methylhexylaminocarbonylthiazol-2-oxy)-2-propanol and pharmaceutically acceptable salts thereof.
 20. The compound of claim 16 wherein said compound is selected from the group consisting of 1-t-butylamino-3-(5-4''-methylhexylaminocarbonylthiazol-2-oxy)2-propanol and pharmaceutically acceptable salts thereof.
 21. The compound of claim 16 wherein said compound is selected from the group consisting of 1-isopropylamino-3-(5-4''-methylhexylaminocarbonylthiazol-2-oxy)-2-propanol and pharmaceutically acceptable salts thereof.
 22. The compound of claim 16 wherein said compound is selected from the group consisting of 1-( Beta -(4-aminocarbonylphenoxy)-ethylamino)-3-(5-4'' -methylhexylaminocarbonylthiazol-2-oxy)-2-propanol and pharmaceutically acceptable salts thereof.
 23. The compound of claim 14 wherein said compound is a hydrochloride salt.
 24. The compound of claim 23 wherein said compound is 1-t-butylamino-3-(5-5''-methylhexylaminocarbonylthiazo-2-oxy)-2-propanol hydrochloride.
 25. The compound of claim 1 wherein Z is the group having the formula
 26. The compound of claim 1 wherein said compound is selected from the group having the formula:
 27. The compound of claim 26 wherein one of R1 or R2 is hydrogen, and R3 is hydrogen.
 28. The compound of claim 26 wherein one of R1 or R2 is hydrogen and the other is selected from the group of isopropyl, sec-butyl, t-butyl, cyclopropyl, cyclopentyl, Alpha -phenylethyl, Alpha -phenylpropyl, Beta -(3,4-dimethoxyphenyl)-ethyl, Beta -(4-hydroxyphenyl)-ethyl, Alpha -methyl- Beta -(4-hydroxyphenyl)-ethyl; gamma -(4-hydroxyphenyl)-propyl, Alpha -methyl- gamma -(4-hydroxyphenyl)-propyl; Alpha -methyl- gamma -phenylpropyl, Beta -(4-aminocarbonylphenoxy)-ethyl and Beta -hydroxyethyl.
 29. The compounds of claim 26 wherein one of R1 or R2 is hydrogen and R4 is selected from the group consisting of 3''-methylhexyl, 1''-methylhexyl, 4''-ethylhexyl, 3''-propylhexyl, n-pentyl, n-hexyl, n-heptyl, n1octyl, cycloheptyl, cyclohexyl, Beta -cyclopentylethyl, gamma -cyclopentylpropyl, 4''-cyclopentylbutyl, gamma -cyclohexylpropyl, 4''-methylhexyl, 5''-methylhexyl, benzyl, Beta -methoxyethyl and gamma -dimethylaminopropyl.
 30. The compound of claim 28 wherein R3 is hydrogen and R4 is selected from the group consisting of 3''-methylhexyl, 1''-methylhexyl, 4''-ethylhexyl, 3''-propylhexyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, cycloheptyl, cyclohexyl, Beta -cyclopentylethyl, gamma -cyclopentylpropyl, 4''-cyclopentylbutyl, gamma -cyclohexylpropyl, 4''-methylhexyl, 5''-methylhexyl, benzyl, Beta -methoxyethyl and gamma -dimethylaminopropyl.
 31. The compound of claim 30 wherein R3 is hydrogen; R4 is selected from the group of 5''-methylhexyl, 4''-methylhexyl, n-hexyl and n-heptYl; and one of R1 or R2 is hydrogen and the other is selected from the group of isopropyl, t-butyl and Beta -(4-aminocarbonylphenoxy)-ethyl.
 32. The compound of claim 31 wherein said compound is selected from the group consisting of 1-t-butylamino-3-(5-5''-methylhexylcarbonylaminothiazol-2-oxy)-2-propanol and pharmaceutically acceptable salts thereof.
 33. The compound of claim 31 wherein said compound is selected from the group consisting of 1-isopropylamino-3-(5-5''-methylhexylcarbonylaminothiazol-2-oxy)-2-propanol and pharmaceutically acceptable salts thereof.
 34. The compound of claim 31 wherein said compound is selected from the group consisting of 1-( Beta -(4-aminocarbonylphenoxy)-ethylamino)-3-(5-5'' -methylhexylcarbonylaminothiazol-2-oxy)-2-propanol and pharmaceutically acceptable salts thereof.
 35. The compound of claim 31 wherein said compound is selected from the group consisting of 1-t-butylamino-3-(5-4''-methylhexylcarbonylaminothiazol-2-oxy)-2-propanol and pharmaceutically acceptable salts thereof.
 36. The compound of claim 31 wherein said compound is selected from the group consisting of 1-isopropylamino-3-(5-4''-methylhexylcarbonylaminothiazol-2-oxy)-2-propanol and pharmaceutically acceptable salts thereof.
 37. The compound of claim 31 wherein said compound is selected from the group consisting of 1-( Beta -(4-aminocarbonylphenoxy)-ethylamino)-3-(5-4'' -methylhexylcarbonylaminothiazol-2-oxy)-2-propanol and pharmaceutically acceptable salts thereof.
 38. The compound of claim 1 wherein Z has the formula
 39. The compound of claim 1 wherein said compound is selected from the group having the formula:
 40. The compound of claim 39 wherein one of R1 or R2 is hydrogen, and R3 is hydrogen.
 41. The compound of claim 39 wherein one of R1 or R2 is hydrogen and the other is selected from the group of isopropyl, sec-butyl, t-butyl, cyclopropyl, cyclopentyl, Alpha -phenylethyl, Alpha -phenylpropyl, Beta -(3,4-dimethoxyphenyl)-ethyl, Beta -(4-hydroxyphenyl)-ethyl, Alpha -methyl- Beta -(4-hydroxyphenyl)-ethyl; gamma -(4-hydroxyphenyl)-propyl, Alpha -methyl- gamma -(4-hydroxyphenyl)-propyl; Alpha -methyl- gamma -phenylpropyl, Beta -(4-aminocarbonylphenoxy)-ethyl and Beta -hydroxyethyl.
 42. The compound of claim 39 wherein one of R1 or R2 is hydrogen and R4 is selected from the group consisting of 3''-methylhexyl, 1''-methylhexyl, 4''-ethylhexyl, 3''-propylhexyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, cycloheptyl, cyclohexyl, Beta -cyclopentylethyl, gamma -cyclopentylpropyl, 4''-cyclopentylbutyl, gamma -cyclohexylpropyl, 4''-metheylhexyl, 5''-methylhexyl, benzyl, Beta -methoxyethyl and gamma -dimethylaminopropyl.
 43. The compound of claim 41 wherein R3 is hydrogen and R4 is selected from the group consisting of 3''-methylhexyl, 1''-methylhexyl, 4''-ethylhexyl, 3''-propylhexyl, n-heptyl, n-octyl, cycloheptyl, cyclohexyl, Beta -cyclopentylethyl, gamma -cyclopentylpropyl, 4''-cyclopentylbutyl, gamma -cyclohexylpropyl, 4''-methylhexyl and 5''-methylhexyl.
 44. The compound of claim 43 wherein R3 is hydrogen; R4 is selected from the group of 5''-methylhexyl, 4''-methylhexyl, and heptyl; and one of R1 or R2 is hydrogen and the other is selected from the group of isopropyl, t-butyl and Beta -(4-amioncarbonylphenoxy)-ethyl.
 45. The compound of claim 44 whewrein said compound is selected from the group consisting of 1-t-butylamino-3-(5-5''-methylhexoxycarbonylaminothiazol-2-oxy)-2-propanol and pharmaceutically acceptable salts thereof.
 46. The compound of claim 44 wherein said compound is selected from the group consisting of 1-isopropylamino-3-(5-5''-methylhexoxycarbonylaminothiazol-2-oxy)-2-propanol and pharmaceutically acceptable salts thereof.
 47. The compound of claim 44 wherein said compound is selected from the group consisting of 1-( Beta -(4-aminocarbonylphenoxy)-ethylamino)-3-(5-5= -methylhexoxycarbonylaminothiazol-2-oxy)-2-propanol and pharmaceutically acceptable salts thereof.
 48. The compound of claim 44 wherein said compound is selected from the group consisting of 1-t-butylamino-3-(5-4''-methylhexoxycarbonylaminothiazol-2-oxy)-2-propanol and pharmaceutically acceptable salts thereof.
 49. The compound of claim 44 wherein said compound is selected from the group consisting of 1-isopropylamino-3-(5-4''-methylhexoxycarbonylaminothiazol-2-oxy)-2-propanol and pharmaceutically acceptable salts thereof.
 50. The compound of claim 44 wherein said compound is selected from the group consisting of 1-( Beta -(4-aminocarbonylphenoxy)-ethylamino)-3-(5-4'' -methylhexoxycarbonylaminothiazol-2-oxy)-2-propanol and pharmaceutically acceptable salts thereof. 